Background: Precisely predicting clinical responses of anti-cancer drugs is a critical issue in the field of pharmacogenomics.The clinical data of patients provided by TCGA including clinical variables along with omics data on different platforms across multiple cancer types could be useful for research on responses of anti-cancer drugs.Based on the Pan-cancer project that proves molecular data from different cancer types share common characteristics, we assume that pan-cancer analysis may improve the performance on predicting clinical responses of anti-cancer drugs.